On 6 May 2022, the Lifecare Annual General Meeting (AGM) passed a resolution authorizing the Board of Directors to establish an incentive program for employees and consultants in the Lifecare Group. The AGM resolution included an authorization for the Board to increase the share capital by up to 5% of the existing registered share capital for use in an incentive program. On this base, Lifecare’s Board of Directors has decided to establish an incentive program including option grants to the company’s executive management and key employees:
- Lifecare CEO, Joacim Holter, has been granted a total of 1.496.115 options with performance-based vesting terms.
- Lifecare CSO, Prof. Andreas Pfützner, has been granted a total of 748.058 options with performance-based vesting terms.
- Other key personnel in the Lifecare Group have each been granted 25.000 options that can be vested at the earliest 3 years from the date of grant.
In addition, the Board of Directors has mandated the CEO to grant up to 20.000 options per employee in the Lifecare Group to defined key personnel based on performance target vesting terms. Furthermore, all employees in the Lifecare Group will be invited to participate in a Share Purchase Program with a 25% discount per share and financing based on a payroll deduction over 12 months, for up to 20.000 shares per employee.
All options will be valid for 5 years from the date of grant. Price per share under the incentive program is defined to be based on the volume-weighted average price of the ordinary shares on the principal market for a period of 10 consecutive trading days prior to the date of grant. Assuming 100% participation in the Share Purchase Program, 100% allocation and achievement of option performance targets, as well as the said time factor of three years for the group of key personnel, the execution of the implemented incentive program will have a total scope of 2.604.173 shares, i.e. slightly above 2,5% of the existing registered share capital of Lifecare AS.
This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).
Further information: Joacim Holter, CEO, Lifecare AS, email@example.com, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 23 May 2022 at 21:00 CET.